Katoh Kiyosi, Taniguchi Hitomi, Okouchi Akiko, Kudo Makoto, Kawai Takako
Department of Internal Medicine, Yokohama General Hospital, 2201 Kurogane-cho, Aoba-ku, Yokohama.
Nihon Kokyuki Gakkai Zasshi. 2004 Aug;42(8):782-6.
A 72-year-old man who had been suffering from rheumatoid arthritis for 25 years developed pulmonary tuberculosis after treatment with infliximab. He had been receiving this treatment since December 2003. Forty-six days later, a fever developed and the patient was hospitalized on February 3, 2004. Chest radiography and chest CT showed an infiltrative shadow with cavity formation. Mycobacterium tuberculosis was detected in the sputum. Infliximab is a monoclonal antibody toward tumor necrosis factor alpha (TNFalpha). It has been reported that infliximab increases the risk of tuberculosis in patients with rheumatoid arthritis in Europe and North America. This is the first case of pulmonary tuberculosis in a patient treated with infliximab in Japan.
一名患类风湿性关节炎25年的72岁男性在使用英夫利昔单抗治疗后患上了肺结核。他自2003年12月起开始接受这种治疗。46天后,患者出现发热,并于2004年2月3日住院。胸部X光和胸部CT显示有浸润性阴影并伴有空洞形成。痰液中检测出结核分枝杆菌。英夫利昔单抗是一种针对肿瘤坏死因子α(TNFα)的单克隆抗体。据报道,在欧洲和北美,英夫利昔单抗会增加类风湿性关节炎患者患肺结核的风险。这是日本首例使用英夫利昔单抗治疗的患者发生肺结核的病例。